Compounded semaglutide ban The U.作者：O Al Musaimi·2025·被引用次数：27—In 2024, theFDAapproved fifty novel drugs, including fourpeptidesand oligonucleotides (TIDEs) (twopepTIDEsand two oligonucleoTIDEs), highlighting their ...S. Food and Drug Administration (FDA) is actively shaping the landscape of peptide therapeutics and related compounds through a series of regulatory updates and enforcement actions. Recent FDA news highlights significant shifts in how peptides, particularly those used in compounding and for research purposes, are being scrutinized. These developments are crucial for understanding the evolving legal and regulatory environment surrounding peptide medications and their availabilityFDA clarifies policies for compounders as national GLP-1 ....
The FDA has been particularly focused on glucagon-like peptide-1 (GLP-1) receptor agonists and the broader peptide industry. In late 2023, the agency updated its list of bulk drug substances, reclassifying several popular peptides as "Category 2," which imposes new limitations on their use by compounding pharmacies2024 FDA TIDES (Peptides and Oligonucleotides) Harvest. This move, set to be fully enforced from January 2025, signifies a stricter approach to compounded peptides, impacting the availability of certain treatments. Furthermore, the FDA has issued warnings regarding unapproved peptide drugs, especially those containing semaglutide, tirzepatide, or retatrutide, which are often falsely labeled for research use only.FDA removes certain peptide bulk drug substances from ... These actions aim to curb the proliferation of potentially unsafe or unproven peptide products entering the market2025年4月3日—Peptides that can be compounded are either:FDA-approved or are FDA GRAS (Generally Recognized as Safe) status,[2] have a USP monograph, appear ....
Compounding pharmacies play a significant role in providing customized medications, including peptides.The current wave of enforcement is now targeting manufacturers ofpeptides, particularly where the supply chain lacks transparency. However, new FDA rules are reshaping this sector. The agency's interim policy revisions on bulk drug substances mean that certain peptides previously available for compounding may now face restrictions.作者：O Al Musaimi·2025·被引用次数：27—In 2024, theFDAapproved fifty novel drugs, including fourpeptidesand oligonucleotides (TIDEs) (twopepTIDEsand two oligonucleoTIDEs), highlighting their ... The regulatory status of peptide compounding in 2025 indicates that only FDA-approved or FDA GRAS (Generally Recognized as Safe) status peptides, or those with a USP monograph, are clearly defined for compounding.A closer look at the unapproved peptide injections ... This clarifies which peptides can be compounded and under what conditions, affecting both providers and consumers seeking these treatments.
The FDA has also addressed specific safety concerns related to GLP-1 receptor agonists.2026年1月13日—TheFDAhas issuednewinformation about glucagon-likepeptide-1 receptor agonists (GLP-1 RAs). See theFDADrug Safety Communication issued ... In early 2026, the agency requested the removal of warnings concerning suicidal behavior and ideation from GLP-1 RA medications, based on updated evaluations.2025年12月8日—EpiVax andFDAScientists PublishNewInsights on Immunogenicity Risks ofPeptide-Related Impurities in Generic Teriparatide. This signifies a reassessment of the risk profile for these widely used drugsThe current wave of enforcement is now targeting manufacturers ofpeptides, particularly where the supply chain lacks transparency.. Simultaneously, the FDA continues to monitor and provide updates on the supply chain for these medications, including clarifying policies for compounders as national shortages, such as for tirzepatide injection, are resolved.
Beyond compounding, the FDA's oversight extends to the research and development of new peptide-based drugs.4天前—Latest news on peptide regulations,FDA actions, state laws, and legal developmentsaffecting the peptide industry. The agency regularly issues Product-Specific Guidances (PSGs) for generic drug development, which are updated quarterly. These guidances are essential for developers seeking to bring generic versions of peptide medications to marketFDA News: Issue 1-1, January 2025. Recent research, such as studies on immunogenicity risks of peptide-related impurities in generic teriparatide, underscores the FDA's commitment to enhancing peptide drug safety through rigorous scientific evaluation and guidance. The FDA has also been involved in designating "Breakthrough Therapy" status for novel peptide treatments, indicating promising advancements in the field.
The peptide industry is experiencing significant growth, partly fueled by the popularity of peptides for various applications, from muscle building to anti-aging, sometimes referred to as "biohacking." This trend has led to an increase in "unapproved peptide injections" and a surge in demand for compounds often sourced through less transparent supply chains2026年1月13日—FDA Requests Removal of Suicidal Behavior and Ideation Warningfrom Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications.. The FDA's heightened enforcement is targeting these areas, particularly where transparency is lacking3天前—The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for litifilimab (BIIB059) for the treatment of .... The agency's focus on "Research Use Only" (RUO) labeling and the supply chain for manufacturers of peptides reflects a proactive stance against the misuse and potential risks associated with these substancesThe current wave of enforcement is now targeting manufacturers ofpeptides, particularly where the supply chain lacks transparency.. As the regulatory environment continues to evolve, staying informed about FDA peptide news updates is crucial for anyone involved in the development, prescription, or use of peptide-based products.
Join the newsletter to receive news, updates, new products and freebies in your inbox.